Legend Biotech Corp ADR (LEGN) Unusual Options Activity Today

Checking LEGN unusual options activity helps you spot when traders are making outsized bets on Legend Biotech Corp ADR before the broader market catches on. Legend Biotech Corp ADR's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor LEGN unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching LEGN unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking LEGN unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and LEGN unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma.

In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Catalysts rarely arrive without a footprint, and LEGN unusual options activity is often where that footprint shows up first. Our scanner tracks Legend Biotech Corp ADR's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at LEGN unusual options volume on the call side or chasing put sweeps, Legend Biotech Corp ADR's unusual options flow today is one click away, so put it on your radar before the headlines hit.